From: Evaluation of prediction models for the staging of prostate cancer
 | PCRC data | OC | NOC | p |
---|---|---|---|---|
 | (n = 603) | (n = 427) | (n = 176) |  |
Age (y) | Â | Â | Â | Â |
Mean (Median) | 61.1 (62) | 60.7 (61) | 62.2 (63) | 0.01 |
Range | 42-74 | 42-74 | 42-74 | Â |
Family history (%) | Â | Â | Â | Â |
PCa history | 151 (25.0) | 107 (25.1) | 46 (28.9) | 0.70 |
Ca history | 121 (20.1) | 85 (19.9) | 26 (16.4) | Â |
No history | 331 (54.9) | 235 (55.0) | 87 (54.7) | Â |
Clinical stage, DRE (%) | Â | Â | Â | Â |
T1c | 267 (44.3) | 188 (44.1) | 79(44.9) | 0.69 |
T2a | 144 (23.9) | 99 (23.1) | 45 (25.6) | Â |
Not reported | 192(31.8) | 140 (32.8) | 52 (39.5) | Â |
PSA (ng/ml) | Â | Â | Â | Â |
Mean (Median) | 7.96 (7.0) | 7.6 (6.7) | 8.6 (7.5) | 0.02 |
Range | 0.7 – 40 | 0.7 – 40 | 2.1 – 36 |  |
Biopsy GS (%) | Â | Â | Â | Â |
5 | 96 (17.4) | 77 (19.7) | 19 (11.8) | P < 0.001 |
6 | 205 (37.1) | 163 (41.7) | 42 (26.1) | Â |
3 + 4 = 7 | 153 (27.7) | 103 (26.3) | 50 (31.1) |  |
4 + 3 = 7 | 46 (8.3) | 22 (5.7) | 24 (14.9) |  |
8 | 34 (6.2) | 18 (4.6) | 16 (9.9) | Â |
9 | 18 (3.3) | 8 (2.0) | 10 (6.2) | Â |
Prostatectomy GS (%) | Â | Â | Â | Â |
5 | 59 (9.8) | 46 (10.8) | 13 (7.4) | P < 0.001 |
6 | 151 (25.0) | 125 (29.2) | 26 (14.8) | Â |
3 + 4 = 7 | 237 (39.3) | 181 (42.4) | 56 (31.8) |  |
4 + 3 = 7 | 90 (14.9) | 44 (10.3) | 46 (26.1) |  |
8 | 42 (7.0) | 20 (4.7) | 22 (12.5) | Â |
9 | 24 (4.0) | 11 (2.6) | 13 (7.4) | Â |
Pathological stage | Â | Â | Â | |
OC | 427 (70) | 427 (70) | - | |
ECE | 111 (19) | - | 111 (63) | |
SVI | 47 (8) | - | 47 (27) | |
LNI | 18 (3) | - | 18 (10) |